204
Views
7
CrossRef citations to date
0
Altmetric
Original Research

From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices

, , , , , & show all
Pages 1093-1110 | Published online: 11 Jul 2019

References

  • Domanska B, Stumpp O, Poon S, Oray S, Mountian I, Pichon C. Using patient feedback to optimize the design of a certolizumab pegol electromechanical self-injection device: insights from human factors studies. Adv Ther. 2018;35(1):100–115. doi:10.1007/s12325-017-0645-129222625
  • Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol. 2015;10(5):345–356. doi:10.2217/ijr.15.3927087857
  • Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol. 2011;5(6):1563–1571. doi:10.1177/19322968110050063322226279
  • Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther. 2004;6(Suppl 2):S19–S23. doi:10.1186/ar99615228617
  • Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2. doi:10.1186/1477-7525-9-4021232106
  • Bailey T, Thurman J, Niemeyer M, Schmeisl G. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin. 2011;27(10):2043–2052. doi:10.1185/03007995.2011.61619021916529
  • Sheikhzadeh A, Yoon J, Formosa D, Domanska B, Morgan D, Schiff M. The effect of a new syringe design on the ability of rheumatoid arthritis patients to inject a biological medication. Appl Ergon. 2012;43(2):368–375. doi:10.1016/j.apergo.2011.05.01421696704
  • Domanska B, VanLunen B, Peterson L, Mountian I, Schiff M. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis. Expert Opin Drug Deliv. 2017;14(1):15–22. doi:10.1080/17425247.2016.125628327801596
  • Gossec L, Berenbaum F, Chauvin P, et al. Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. Clin Rheumatol. 2018;37(10):2649–2657. doi:10.1007/s10067-018-4172-5
  • Gossec L, Chauvin P, Saraux A, et al. Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. Ann Rheum Dis. 2018;77(2):258–263. doi:10.1136/annrheumdis-2017-21200029102955
  • Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. PharmacoEconomics. 2008;26(8):661–677. doi:10.2165/00019053-200826080-0000418620460
  • Skjoldborg US, Lauridsen J, Junker P. Reliability of the discrete choice experiment at the input and output level in patients with rheumatoid arthritis. Value Health. 2009;12(1):153–158. doi:10.1111/j.1524-4733.2008.00402.x19911446
  • Dilla T, Rentero ML, Comellas M, Lizan L, Sacristan JA. Patients’ preferences for rheumatoid arthritis treatments and their participation in the treatment decision-making process. A systematic review of the literature. Value Health. 2015;18(7):A652. doi:10.1016/j.jval.2015.09.2348
  • UCB: UCB receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose dispenser cartridge for use with ava® electronic injection device. Available from: https://www.ucb.com/stories-media/Press-Releases/article/UCB-receives-positive-CHMP-opinion-for-CIMZIA-certolizumab-pegol-dose-dispenser-cartridge-for-use-with-ava-electronic-injection-device. accessed 4, 2018.
  • Collier DH, Bitman B, Coles A, Liu L, Kumar S, Judd C. A novel electromechanical autoinjector, AutoTouch, for self-injection of etanercept: real-world use and benefits. Postgrad Med. 2017;129(1):118–125. doi:10.1080/00325481.2017.125129127829325
  • Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.01321669364
  • Domańska B, Mountian I, Vinconneau G. Patient-preferred design features of TNF inhibitor self-injection devices: insights from a rheumatoid arthritis auto-injector preference study. Value Health. 2017;20(9):A591–A592. doi:10.1016/j.jval.2017.08.1095
  • Schiff M, Saunderson S, Mountian I, Hartley P. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4(2):445–463. doi:10.1007/s40744-017-0080-428956300
  • Ozdemir S, Johnson FR, Hauber AB. Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ. 2009;28(4):894–901. doi:10.1016/j.jhealeco.2009.04.00419464743
  • Kuhfeld WF. Marketing Research Methods in SAS Experimental Design, Choice, Conjoint, and Graphical Techniques. Cary: SAS Institute Inc.; 2009.
  • Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.00427325321
  • Walker JL, Ben‐Akiva M, Bolduc D. Identification of parameters in normal error component logit‐mixture (NECLM) models. J Appl Econom. 2007;22(6):1095–1125. doi:10.1002/(ISSN)1099-1255
  • Greene W. Econometric Analysis. Essex: Pearson Education Limited;  2012:155–161.
  • Hanemann WM. Welfare evaluations in contingent valuation experiments with discrete responses. Am J Agric Econ. 1984;66(3):332–341. doi:10.2307/1240800
  • Kruger K, Alten R, Schiffner-Rohe J, et al. Patient preferences in the choice of disease modifying anti-rheumatic drugs. Ann Rheum Dis. 2015;74(suppl 2):322. doi:10.1136/annrheumdis-2015-eular.2349
  • UCB. Axial spondyloarthritis. 2017 Available from: https://www.ucb.com/disease-areas/axial-spondyloarthritis. accessed 6 2018]
  • UCB. Rheumatoid arthritis. 2017 Available from: https://www.ucb.com/disease-areas/rheumatoid-arthritis accessed 6, 2018.
  • UCB. Psoriatic arthritis. 2017 Available from: https://www.ucb.com/disease-areas/psoriatic-arthritis. accessed 6, 2018.
  • Matfin G, Van Brunt K, Zimmermann AG, Threlkeld R, Ignaut DA. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9(5):1071–1079. doi:10.1177/193229681558305925901022
  • Fraenkel L, Wiedmeyer C, Herath G, Michel G, Nowell B. Development of RA patient preference phenotypes [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
  • Tuominen R, Azbel M, Hemmila J, Mottonen T. Willingness to pay for improvement of physical function among rheumatoid arthritis patients as measured by health assessment questionnaire. Rheumatol Int. 2011;31(3):347–352. doi:10.1007/s00296-009-1280-120020140
  • Slothuus U, Brooks RG. Willingness to pay in arthritis: a Danish contribution. Rheumatology (Oxford). 2000;39(7):791–799. doi:10.1093/rheumatology/39.7.79110908700
  • van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337–351. doi:10.1586/eci.12.2322607180